Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma Journal Article
| Authors: | Arias-Mendoza, F.; Payne, G. S.; Zakian, K.; Stubbs, M.; O'Connor, O. A.; Mojahed, H.; Smith, M. R.; Schwarz, A. J.; Shukla-Dave, A.; Howe, F.; Poptani, H.; Lee, S. C.; Pettengel, R.; Schuster, S. J.; Cunningham, D.; Heerschap, A.; Glickson, J. D.; Griffiths, J. R.; Koutcher, J. A.; Leach, M. O.; Brown, T. R. |
| Article Title: | Noninvasive phosphorus magnetic resonance spectroscopic imaging predicts outcome to first-line chemotherapy in newly diagnosed patients with diffuse large B-cell lymphoma |
| Abstract: | Rationale and Objectives: Based on their association with malignant proliferation, using noninvasive phosphorus MR spectroscopic imaging (31P MRSI), we measured the tumor content of the phospholipid-related phosphomonoesters (PME), phosphoethanolamine and phospholcholine, and its correlation with treatment outcome in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL) receiving standard first-line chemotherapy. Experimental Design: The PME value normalized to nucleoside triphosphates (PME/NTP) was measured using 31P MRSI in tumor masses of 20 patients with DLBCL before receiving standard first-line chemotherapy. Response at 6months was complete in 13 patients and partial in seven. Time to treatment failure (TTF) was ≤11months in eight patients, from 18 to 30months in three, and ≥60months in nine. Results: On a t test, the pretreatment tumor PME/NTP mean value (SD, n) of patients with a complete response at 6months was 1.42 (0.41, 13), which was significantly different from the value of 2.46 (0.40, 7) in patients with partial response (P < .00001). A Fisher test significantly correlated the PME/NTP values with response at 6months (sensitivity and specificity at 0.85, P < .004) while a Cox proportional hazards regression significantly correlated the PME/NTP values with TTF (hazard ratio=5.21, P < .02). A Kaplan-Meier test set apart a group entirely composed of patients with TTF ≤ 11months (hazard ratio=8.66, P < .00001). Conclusions: The pretreatment tumor PME/NTP values correlated with response to treatment at 6months and time to treatment failure in newly diagnosed patients with DLBCL treated with first-line chemotherapy, and therefore they could be used to predict treatment outcome in these patients. © 2013 AUR. |
| Keywords: | adult; cancer chemotherapy; cancer survival; clinical article; treatment outcome; treatment response; aged; aged, 80 and over; middle aged; retrospective studies; young adult; unclassified drug; prednisone; doxorubicin; cytarabine; methotrexate; rituximab; diagnostic accuracy; sensitivity and specificity; reproducibility of results; etoposide; antineoplastic combined chemotherapy protocols; tumor markers, biological; cyclophosphamide; vincristine; prediction; false negative result; lymphoma, b-cell; folinic acid; mitoxantrone; lymphoma; magnetic resonance spectroscopy; bleomycin; large cell lymphoma; drug treatment failure; false positive result; phosphorus nuclear magnetic resonance; predictive value; correlational study; phospholipids; metabolic imaging; phosphoethanolamine; phosphorus 31; phosphorus isotopes; diagnostic test accuracy study; nucleoside triphosphate; invivo; mr spectroscopy; time to treatment; prediction of therapy outcome; phospholcholine; phospholipid derivative; phospholipid related phosphomonoester; in vivo |
| Journal Title: | Academic Radiology |
| Volume: | 20 |
| Issue: | 9 |
| ISSN: | 1076-6332 |
| Publisher: | Elsevier Science, Inc. |
| Date Published: | 2013-09-01 |
| Start Page: | 1122 |
| End Page: | 1129 |
| Language: | English |
| DOI: | 10.1016/j.acra.2013.04.013 |
| PROVIDER: | scopus |
| PUBMED: | 23931426 |
| PMCID: | PMC3810177 |
| DOI/URL: | |
| Notes: | --- - "Export Date: 4 September 2013" - "CODEN: ARADF" - "Source: Scopus" |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work